Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells

Journal of Endocrinology

Volumn 191, Issue 2, 2006, Pages 465-472

  Catalano, Maria G ^a   Fortunati, Nicoletta ^b   Pugliese, Mariateresa ^b   Poli, Roberta ^b   Bosco, Ornella ^a   Mastrocola, Raffaella ^a   Aragno, Manuela ^a   Boccuzzi, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG ACETYLATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CANCER; TREATMENT OUTCOME;

EID: 33751505528     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06970     Document Type: Article

References (45)

1. Abdul M & Hoosein N 2001 Inhibition by anticonvulsivants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Research 21 2045-2048.
2. Adachi N, Nomoto M, Kohno K & Koyama H 2000 Cell-cycle regulation of the DNA topoisomerase II alpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene 245 49-57.
3. Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, Devido D, Mian C & Girelli ME 2000 A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. Journal of Endocrinological Investigation 23 755-761.
4. Catalano MG, Fortunati N, Pugliese M, Costantinc, L, Poh R, Bosco O & Boccuzzi G 2005 Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 90 1383-1389.
5. Chomczynski P & Sacchi N 1987 Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 156-159.
6. De Ruijter Aj, van Gennip AH, Caron FIN, Kemp S & Kuilenburg AB 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal 370 737-749.
7. Dokmanovic M & Marks PA 2005 Prospects: hiscone deacetylase inhibitors. Journal of Cellular Biochemistry 96 293-304.
8. Fleming DI 1997 Cancer Staging Manual., Philadelphia: Lippencott-Raven.
9. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A & Boccuzzi G 2004 Valproic acid induces the expression of the Na + /I - symporter and iodine uptake in poorly differentiated thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 89 1006-1009.
10. Gewirtz DA 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology 57 727-741.
11. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pehcci PG et al. 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 20 6969-6978.
12. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M & Zimmer SG 2001a Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11 315-325.
13. Greenberg VL, Wilhams JM, Boghaert E, Mendenhall M, Ain KB & Zimmer SG 2001b Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 11 21-29.
14. Haigh PI 2000 Anaplastic thyroid carcinoma. Current Treatment Options in Oncology 1 353-357.
15. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY & Clark CH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91 2335-2342.
16. Johnstone RW & Licht JD 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 13-18.
17. Kawagoe R, Kawagoe H & Sano K 2002 Valproic acid induces apoptosis in human leukaemia cells by stimulating both caspase-dependent and - independent apoptotic signaling pathways. Leukemia Research 26 495-502.
18. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y & Carrier F 2003 Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Research 63 7291-7300.
19. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K & Tanaka S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. Journal of Clinical Endocrinology and Metabolism 84 4043-4049.
20. Knupfer MM, Hernaiz-Driever P, Poppenborg H, Wolff JE & Cinatl J 1988 Valproic acid inhibits proliferation and changes expression of CD44 and CD 56 of malignant glioma cells in vitro. Anticancer Research 18 3585-3589.
21. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC & Kroll DJ 2001 The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Molecular Cancer Therapeutics 1 121-131.
22. Lindemann RK, Gabrielli B & Johnstone RW 2004 Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3 779-788.
23. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM & Munster PN 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Journal of Cellular Biochemistry 92 223-237.
24. Marchion DC, Bicaku E, Daud Ad, Sullivan DM & Munster PN 2005 Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Research 65 3815-3822.
25. Marks PA, Richon VM, Breslow R & Rifkind RA 2001a Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology 13 477-483.
26. Marks PA, Richon RA, Richon VM, Breslow R, Miller T & Kelly WK 2001b Histone deacetylases and cancer: causes and therapies. Nature Reviews. Cancer 1 194-202.
27. Massart C, Poirier C, Fergelot P, Fardel O & Gibassier J 2005 Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. Anticancer Drugs 16 255-261.
28. Mikhailov A, Shinohara M & Rieder CL 2004 Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. Journal of Cell Biology 166 517-526.
29. Minotti G, Menna P, Salvatorelli E, Cairo G & Gianni L 2004 Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 56 185-229.
30. Mitsiades CS, Poulaki V, McMullan C, Negri, Fanourakis G, Goudopoulou A, Richon VM, Marks PA & Mitsiades N 2005 Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clinical Cancer Research 11 3958-3965.
31. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoro-Yamaguchi Y, Umeda M & Honma Y 2000 Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cycotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Molecular Pharmacology 58 27-36.
32. Olsen CM, Meussen-Elhom ETM, Roste LS & Tauboll E 2004 Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF-7. Molecular and Cellular Endocrinology 213 173-179.
33. Parker CS & Topol JA 1984 Drosophila RNA polymerase II transcription factor contains a promoter-region-specific DNA-binding activity. Cell 36 357-369.
34. Pasieka JL 2003 Anaplastic thyroid cancer. Current Opinion in Oncology 15 78-83.
35. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA & Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276 36734-36741.
36. Ravindranath V 1994 Animal models and molecular markers for cerebral ischerma-reperfusion injury in brain. Methods in Enzymology 233 610-619.
37. Rho JH, Kang DY, Park KJ, Choi HJ, Lee HS, Yee SB & Yoo YH 2005 Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation. International Journal of Oncology 27 465-471.
38. Rosato RR. & Grant S 2003 Histone deacetylase inhibitors in cancer therapy. Cancer Biology and Therapy 2 30-37.
39. Sinha BK 1989 Free radicals in anticancer drug pharmacology. Chemico-Biological Interactions 69 293-317.
40. Slesinger PA & Singer HS 1987 Effect of anticonvulsants on cell growth and enzymatic and receptor binding activity in neuroblastoma X glioma hybrid cell culture. Epilepsia 28 214-221.
41. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I & Koeffier HP 2004 Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical Cancer Research 10 1141-1149.
42. Tewey KM, Chen GL, Nelson EM & Liu LF 1984 Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry 259 9182-9187.
43. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D & Seto E 2000 Histone deacetylase interacts directly with DNA topoisomerase II. Nature Genetics 26 349-353.
44. Veness MJ, Porter GS & Morgan GJ 2004 Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ Journal of Surgery 74 559-562.
45. Vigushin DM & Coombes RC 2002 Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 12 1-13.